Predicting Pathway Dependency in Head and Neck Squamous Cell Carcinoma from Hallmark Transcriptomic Features
- 1USERN
Abstract
Despite frequent pathway activation, targeted molecular therapy remains limited in head and neck squamous cell carcinoma (HNSCC), highlighting the need to distinguish activation from dependence. Dependency is functional, context-specific, and coupled; mutations or expression alone cannot establish it. No validated framework identifies tumor pathway dependencies from baseline molecular profiles. We developed a transcriptome-based framework to infer pathway dependency in HNSCC. Nine Elastic Net models used 50 MSigDB Hallmark activity profiles from 953 GDSC cell lines and drug responses pooled across compounds annotated to each pathway. Cross-validated R2 ranged from 0.17 (IGF1R) to 0.48 (P53); leave-one-pathway-out validation retained rank agreement (Spearman {rho} = 0.19-0.56) for pathways with no drug response observed during training. We validated the models using pharmacological, genomic, and proteomic data, then applied them to TCGA-HNSC (n = 565) and GSE65858 (n = 256), examining HPV status, age, stage, tobacco history, and CD8+ infiltration. Seven of nine pathways were higher in HPV+ tumors and replicated directionally in GSE65858. Among TP53-wild-type tumors, HPV remained linked to greater P53 dependency ({beta} = +0.37, q = 0.010); HPV+ tumors also had higher p53 transcriptional activity, suggesting residual p53 function despite E6 expression. The codependency signature had a dominant global axis (PC1 = 62.3% variance; Cronbach's = 0.91), replicated across cohorts (Tucker congruence = 0.996), but largely reflected CD8+ T-cell infiltration ({rho} = 0.80). The framework uses RNA-sequenced bulk tumor cohorts to assess baseline transcriptome-based dependencies and match pathway-directed agents to likely responders before treatment. It is not prognostic.
Related
- Integrated Transcriptomic and CRISPR Dependency Analysis Prioritizes a CDK1-AURKB Mitotic Vulnerability Axis in Diffuse Intrinsic Pontine Glioma
- Testing immune priming failure in laryngeal squamous cell carcinoma: direct evidence, unresolved links, and a compartment-resolved framework
- Chemopreventive potential of Styrax liquidus in a DMBA-induced oral squamous cell carcinoma model
- Novel Target Combinations in Lung Squamous Cell Carcinoma proposed by the Emet AI Research Environment and supported by discovery stage experimentation
- Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma
BibTeX
@misc{afshar2026predicting,
title = {{Predicting Pathway Dependency in Head and Neck Squamous Cell Carcinoma from Hallmark Transcriptomic Features}},
author = {Y. Afshar and A. Goli},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.26.761775},
url = {https://www.biorxiv.org/content/10.64898/2026.10.26.761775v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Predicting Pathway Dependency in Head and Neck Squamous Cell Carcinoma from Hallmark Transcriptomic Features
AU - Y. Afshar
AU - A. Goli
PY - 2026
DA - 2026/10/26
PB - bioRxiv
DO - 10.64898/2026.10.26.761775
UR - https://www.biorxiv.org/content/10.64898/2026.10.26.761775v1
AB - Despite frequent pathway activation, targeted molecular therapy remains limited in head and neck squamous cell carcinoma (HNSCC), highlighting the need to distinguish activation from dependence. Dependency is functional, context-specific, and coupled; mutations or expression alone cannot establish it. No validated framework identifies tumor pathway dependencies from baseline molecular profiles. We developed a transcriptome-based framework to infer pathway dependency in HNSCC. Nine Elastic Net models used 50 MSigDB Hallmark activity profiles from 953 GDSC cell lines and drug responses pooled across compounds annotated to each pathway. Cross-validated R2 ranged from 0.17 (IGF1R) to 0.48 (P53); leave-one-pathway-out validation retained rank agreement (Spearman {rho} = 0.19-0.56) for pathways with no drug response observed during training. We validated the models using pharmacological, genomic, and proteomic data, then applied them to TCGA-HNSC (n = 565) and GSE65858 (n = 256), examining HPV status, age, stage, tobacco history, and CD8+ infiltration. Seven of nine pathways were higher in HPV+ tumors and replicated directionally in GSE65858. Among TP53-wild-type tumors, HPV remained linked to greater P53 dependency ({beta} = +0.37, q = 0.010); HPV+ tumors also had higher p53 transcriptional activity, suggesting residual p53 function despite E6 expression. The codependency signature had a dominant global axis (PC1 = 62.3% variance; Cronbach's = 0.91), replicated across cohorts (Tucker congruence = 0.996), but largely reflected CD8+ T-cell infiltration ({rho} = 0.80). The framework uses RNA-sequenced bulk tumor cohorts to assess baseline transcriptome-based dependencies and match pathway-directed agents to likely responders before treatment. It is not prognostic.
ER -